| Dr Fatima Janjua, MD | |
|
450 E. Huntington Drive, Arcadia, CA 91006-3748 | |
| (626) 462-1884 | |
| (626) 445-1542 |
| Full Name | Dr Fatima Janjua |
|---|---|
| Gender | Female |
| Speciality | Neurology |
| Experience | 27 Years |
| Location | 450 E. Huntington Drive, Arcadia, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366485203 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | A78822 (California) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Healthcare Partners Affiliates Medical Group | 7315842002 | 658 |
News Archive
AcelRx Pharmaceuticals, Inc. today announced positive results from a Phase 2 clinical trial of ARX-03, a proprietary sublingual dosage form combining an opioid, sufentanil, with a benzodiazepine, triazolam.
Trigeminal neuralgia, or TN, is a disorder affecting the areas of the face where the trigeminal nerve's branches are distributed, including the lips, eyes, nose, scalp, forehead, and upper and lower jaws.
Arteriocyte, a leading biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts announced today approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan MAR01 technology in the treatment of Compartment Syndrome.
A recent trend analysis indicates that cervical cancer incidence and mortality rates have remained stable or are dropping in most countries across the globe.
Most young athletes don't get enough sleep - and that may significantly affect their sports performance, according to a paper in the November issue of Current Sports Medicine Reports, official journal of the American College of Sports Medicine.
› Verified 7 days ago
| Entity Name | Healthcare Partners Affiliates Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659312593 PECOS PAC ID: 7315842002 Enrollment ID: O20031204001258 |
News Archive
AcelRx Pharmaceuticals, Inc. today announced positive results from a Phase 2 clinical trial of ARX-03, a proprietary sublingual dosage form combining an opioid, sufentanil, with a benzodiazepine, triazolam.
Trigeminal neuralgia, or TN, is a disorder affecting the areas of the face where the trigeminal nerve's branches are distributed, including the lips, eyes, nose, scalp, forehead, and upper and lower jaws.
Arteriocyte, a leading biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts announced today approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan MAR01 technology in the treatment of Compartment Syndrome.
A recent trend analysis indicates that cervical cancer incidence and mortality rates have remained stable or are dropping in most countries across the globe.
Most young athletes don't get enough sleep - and that may significantly affect their sports performance, according to a paper in the November issue of Current Sports Medicine Reports, official journal of the American College of Sports Medicine.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Fatima Janjua, MD 450 E. Huntington Drive, Arcadia, CA 91006-3748 Ph: () - | Dr Fatima Janjua, MD 450 E. Huntington Drive, Arcadia, CA 91006-3748 Ph: (626) 462-1884 |
News Archive
AcelRx Pharmaceuticals, Inc. today announced positive results from a Phase 2 clinical trial of ARX-03, a proprietary sublingual dosage form combining an opioid, sufentanil, with a benzodiazepine, triazolam.
Trigeminal neuralgia, or TN, is a disorder affecting the areas of the face where the trigeminal nerve's branches are distributed, including the lips, eyes, nose, scalp, forehead, and upper and lower jaws.
Arteriocyte, a leading biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts announced today approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan MAR01 technology in the treatment of Compartment Syndrome.
A recent trend analysis indicates that cervical cancer incidence and mortality rates have remained stable or are dropping in most countries across the globe.
Most young athletes don't get enough sleep - and that may significantly affect their sports performance, according to a paper in the November issue of Current Sports Medicine Reports, official journal of the American College of Sports Medicine.
› Verified 7 days ago
M. Lorraine Purino, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 665 W Naomi Ave, Ste. 201, Arcadia, CA 91007 Phone: 626-445-8481 Fax: 626-574-9669 | |
Mrs. Gayane Aghakhanyan, M.D Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 330 E Live Oak Ave, Arcadia, CA 91006 Phone: 626-254-1400 Fax: 626-447-4792 | |
Marita G Cristobal, Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 330 E Live Oak Ave, Arcadia, CA 91006 Phone: 626-821-5858 Fax: 626-821-0858 | |
James Quines, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 330 E Live Oak Ave, Arcadia, CA 91006 Phone: 626-254-1400 | |
Dr. Linda Lanlan Wang, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 330 E Live Oak Ave, Arcadia, CA 91006 Phone: 626-821-5858 Fax: 626-821-0858 | |
Dr. Vincent M Fortanasce, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 665 W Naomi Ave Ste 201, Arcadia, CA 91007 Phone: 626-445-8481 Fax: 626-574-9669 | |
Dr. John Stewart Wells, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 330 E Live Oak Ave, Arcadia, CA 91006 Phone: 626-821-5858 Fax: 626-821-0858 |